Disc Medicine Inc（IRON）の財務IRONDisc Medicine Inc

Evaluating the bottom line, Disc Medicine, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -39.08%, provide a clear picture of how effectively IRON converts its operational activities into shareholder value.

In the context of the broader market, IRON competes directly with industry leaders such as DYN and DNLI. With a market capitalization of $3.45B, it holds a leading position in the sector. When comparing efficiency, IRON's gross margin of N/A stands against DYN's N/A and DNLI's 76.61%. Such benchmarking helps identify whether Disc Medicine, Inc. is trading at a premium or discount relative to its financial performance.

Disc Medicine has shown a consistent negative net income with losses increasing to -$63.5 million in Q1 2026 and -$59.5 million in Q2 2026. Despite these losses, the company has a strong cash position and a current ratio of 24.14, indicating good liquidity.